AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
226.08
-2.63 (-1.15%)
At close: Dec 5, 2025, 4:00 PM EST
226.45
+0.37 (0.16%)
After-hours: Dec 5, 2025, 7:55 PM EST
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,084,436
Profits / Employee
$42,691
Market Cap
399.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABBV News
- 1 day ago - Could Buying AbbVie Today Set You Up for Life? - The Motley Fool
- 2 days ago - AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - PRNewsWire
- 3 days ago - 2 Top Dividend Stocks to Buy Now and Hold For a Decade - The Motley Fool
- 4 days ago - AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating - Seeking Alpha
- 6 days ago - 3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years - The Motley Fool
- 6 days ago - Best Dividend Aristocrats For December 2025 - Seeking Alpha
- 7 days ago - SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - GlobeNewsWire